No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins

Journal of Clinical Lipidology

Volumn 4, Issue 4, 2010, Pages 288-292

  Hovland, Anders ^a,b   Aagnes, AInger ^a   Brekke, Ole Lars ^a,b   Flage, John Helge ^a   Lappegard, Knut Tore ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Endothelial function; Familial hypercholesterolemia; Inflammation; LDL cholesterol; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INFLAMMATION; PRIORITY JOURNAL; ADULT; AGE; BLOOD; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HYPERLIPOPROTEINEMIA TYPE 2; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION MEDIATORS; MIDDLE AGED;

EID: 79959657927     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.02.011     Document Type: Article

References (35)

1. Scientific Steering Committee om behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Atherosclerosis. 1999;142: 105-112.
2. Neil HA, Huxley RR, Hawkins MM, Durrington PN, Betteridge DJ, Humphries SE. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: A prospective registry study. Atherosclerosis. 2003;170:73-78.
3. National Institute for Health and Clinical Excellence. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults And Children With Familial Hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
4. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in the Netherlands. Atherosclerosis. 2010; 209:189-194.
5. Cheng HM, Ye ZX, Chiou KR, Lin SJ, Charng MJ. Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. Eur J Clin Invest. 2007;37:197-206.
6. Kastelein JJ, Wiegman A, de Groot E. Surrogate markers of atherosclerosis: Impact of statins. Atheroscler Suppl. 2003;4:31-36.
7. Junyent M, Gilabert R, Jarauta E, et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2010;208:437-441.
8. Truschel E, Jarczok MN, Fischer JE, Terris DD. High-throughput ambulatory assessment of digital reactive hyperemia: Concurrent validity with known cardiovascular risk factors and potential confounding. Prev Med. 2009;49:468-472.
9. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr., Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137-2141.
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
11. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-677.
12. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55-61.
13. Healy B. Endothelial cell dysfunction: An emerging endocrinopathy linked to coronary disease. J Am Coll Cardiol. 1990;16:357-358.
14. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467-2474.
15. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol. 2004;160:407-420.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-1278.
18. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
19. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846-851.
20. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endotheliumdependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
21. Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196-201.
22. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251.
23. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
24. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
25. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168-174.
26. Patvardhan EA, Heffernan KS, Ruan JM, Soffler MI, Karas RH, Kuvin JT. Assessment of vascular endothelial function with peripheral arterial tonometry: Information at your fingertips? Cardiol Rev. 2010; 18:20-28.
27. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009;19: 6-11.
28. Haller MJ, Stein J, Shuster J, et al. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes. 2007;8:193-198.
29. Mahmud FH, Van US, Kanji N, Thiessen-Philbrook H, Clarson CL. Impaired endothelial function in adolescents with type 1 diabetes mellitus. J Pediatr. 2008;152:557-562.
30. Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): A pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009;22:65-68.
31. Charakida M, Tousoulis D, Skoumas I, et al. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204:532-537.
32. Guardamagna O, Abello F, Saracco P, Baracco V, Rolfo E, Pirro M. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. 2009;207: 471-475.
33. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
34. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695.
35. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.